Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

A number of other brokerages have also recently commented on SCMP. ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 7th. Mizuho increased their target price on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, December 8th. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, December 7th. B. Riley increased their target price on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.60.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up $0.25 during midday trading on Tuesday, reaching $17.00. The company had a trading volume of 2,576,738 shares, compared to its average volume of 2,216,589. The firm has a market cap of $792.81, a PE ratio of 11.64, a price-to-earnings-growth ratio of 5.06 and a beta of 1.47. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.70. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. The company had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 EPS. equities analysts anticipate that Sucampo Pharmaceuticals will post 1.12 EPS for the current fiscal year.

In other news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.13% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares during the period. JPMorgan Chase & Co. acquired a new position in Sucampo Pharmaceuticals during the second quarter worth $117,000. Pinnacle Associates Ltd. acquired a new position in Sucampo Pharmaceuticals during the second quarter worth $122,000. Trexquant Investment LP acquired a new position in Sucampo Pharmaceuticals during the third quarter worth $122,000. Finally, SG Americas Securities LLC lifted its stake in Sucampo Pharmaceuticals by 5.6% during the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 631 shares in the last quarter. Institutional investors own 65.31% of the company’s stock.

WARNING: “Sucampo Pharmaceuticals (SCMP) Upgraded to “Strong-Buy” by BidaskClub” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/17/sucampo-pharmaceuticals-scmp-upgraded-to-strong-buy-by-bidaskclub.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.